PACB vs. ILMN

Last updated Apr 1, 2026

Compare and contrast key facts about Pacific Biosciences of California, Inc. (PACB) and Illumina, Inc. (ILMN).

Performance

PACB vs. ILMN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pacific Biosciences of California, Inc. (PACB) and Illumina, Inc. (ILMN). The values are adjusted to include any dividend payments, if applicable.

PACB vs. ILMN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
PACB Pacific Biosciences of California, Inc.	-29.41%	2.19%	-81.35%	19.93%	-60.02%	-21.13%	404.67%	-30.54%	180.30%	-30.53%
ILMN Illumina, Inc.	-6.02%	-1.85%	-1.34%	-31.14%	-46.85%	2.82%	11.53%	10.61%	37.27%	70.64%

Fundamentals

Market Cap PACB : $398.52M ILMN : $18.98B
EPS PACB : -$1.82 ILMN : $5.44
PS Ratio PACB : 2.48 ILMN : 4.44
PB Ratio PACB : 74.50 ILMN : 6.16
Total Revenue (TTM) PACB : $160.01M ILMN : $4.34B
Gross Profit (TTM) PACB : $50.67M ILMN : $2.89B
EBITDA (TTM) PACB : -$161.03M ILMN : $1.46B

Returns By Period

In the year-to-date period, PACB achieves a -29.41% return, which is significantly lower than ILMN's -6.02% return. Over the past 10 years, PACB has underperformed ILMN with an annualized return of -17.78%, while ILMN has yielded a comparatively higher -2.71% annualized return.

PACB

• 1D: 4.76%
• 1M: -21.43%
• YTD: -29.41%
• 6M: 3.13%
• 1Y: 11.86%
• 3Y*: -51.51%
• 5Y*: -47.73%
• 10Y*: -17.78%

ILMN

• 1D: 2.03%
• 1M: -8.33%
• YTD: -6.02%
• 6M: 29.79%
• 1Y: 55.36%
• 3Y*: -18.32%
• 5Y*: -19.93%
• 10Y*: -2.71%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

PACB vs. ILMN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PACB

PACB Risk / Return Rank: 50
PACB Sharpe Ratio Rank: 47
PACB Sortino Ratio Rank: 55
PACB Omega Ratio Rank: 49
PACB Calmar Ratio Rank: 49
PACB Martin Ratio Rank: 49

ILMN

ILMN Risk / Return Rank: 77
ILMN Sharpe Ratio Rank: 78
ILMN Sortino Ratio Rank: 78
ILMN Omega Ratio Rank: 73
ILMN Calmar Ratio Rank: 79
ILMN Martin Ratio Rank: 78

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PACB vs. ILMN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and Illumina, Inc. (ILMN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PACB	ILMN	Difference
Sharpe ratio Return per unit of total volatility	0.13	1.14	-1.01
Sortino ratio Return per unit of downside risk	0.96	1.94	-0.99
Omega ratio Gain probability vs. loss probability	1.10	1.23	-0.13
Calmar ratio Return relative to maximum drawdown	0.30	2.11	-1.81
Martin ratio Return relative to average drawdown	0.63	5.22	-4.59
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PACB vs. ILMN - Sharpe Ratio Comparison

The current PACB Sharpe Ratio is 0.13, which is lower than the ILMN Sharpe Ratio of 1.14. The chart below compares the historical Sharpe Ratios of PACB and ILMN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	PACB	ILMN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.13	1.14	-1.01
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.51	-0.44	-0.07
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.21	-0.06	-0.15
Sharpe Ratio (All Time) Calculated using the full available price history	-0.18	0.13	-0.31

Correlation

The correlation between PACB and ILMN is 0.39, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

PACB vs. ILMN - Dividend Comparison

Neither PACB nor ILMN has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

PACB vs. ILMN - Drawdown Comparison

The maximum PACB drawdown since its inception was -98.22%, roughly equal to the maximum ILMN drawdown of -96.14%. Use the drawdown chart below to compare losses from any high point for PACB and ILMN.

Drawdown Indicators

	PACB	ILMN	Difference
Max Drawdown Largest peak-to-trough decline	-98.22%	-96.14%	-2.08%
Max Drawdown (1Y) Largest decline over 1 year	-52.81%	-25.66%	-27.15%
Max Drawdown (5Y) Largest decline over 5 years	-97.47%	-86.23%	-11.24%
Max Drawdown (10Y) Largest decline over 10 years	-98.22%	-86.23%	-11.99%
Current Drawdown Current decline from peak	-97.42%	-75.86%	-21.56%
Average Drawdown Average peak-to-trough decline	-70.20%	-40.15%	-30.05%
Ulcer Index Depth and duration of drawdowns from previous peaks	24.93%	10.36%	+14.57%

Volatility

PACB vs. ILMN - Volatility Comparison

Pacific Biosciences of California, Inc. (PACB) has a higher volatility of 19.48% compared to Illumina, Inc. (ILMN) at 10.88%. This indicates that PACB's price experiences larger fluctuations and is considered to be riskier than ILMN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PACB	ILMN	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.48%	10.88%	+8.60%
Volatility (6M) Calculated over the trailing 6-month period	66.55%	36.52%	+30.03%
Volatility (1Y) Calculated over the trailing 1-year period	91.97%	49.01%	+42.96%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.91%	45.30%	+48.61%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	84.47%	42.62%	+41.85%

Financials

PACB vs. ILMN - Profitability Comparison

The chart below illustrates the profitability comparison between Pacific Biosciences of California, Inc. and Illumina, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

PACB - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Pacific Biosciences of California, Inc. reported a gross profit of 21.46M and revenue of 44.65M. Therefore, the gross margin over that period was 48.1%.

ILMN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Illumina, Inc. reported a gross profit of 777.00M and revenue of 1.16B. Therefore, the gross margin over that period was 67.0%.

PACB - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Pacific Biosciences of California, Inc. reported an operating income of -41.20M and revenue of 44.65M, resulting in an operating margin of -92.3%.

ILMN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Illumina, Inc. reported an operating income of 256.00M and revenue of 1.16B, resulting in an operating margin of 22.1%.

PACB - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Pacific Biosciences of California, Inc. reported a net income of -40.37M and revenue of 44.65M, resulting in a net margin of -90.4%.

ILMN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Illumina, Inc. reported a net income of 334.00M and revenue of 1.16B, resulting in a net margin of 28.8%.